9 Meters Biopharma, Inc., is a clinical-stage company pioneering novel treatments for people with rare digestive diseases, GI conditions with unmet needs, and debilitating disorders in which the ...

The 9 Meters Analyst: Analyst Sally Yanchus initiated coverage of 9 Meters shares with a Buy rating and $5 price target, suggesting about 800% upside potential from current levels.

Sec Form 4 filings submitted by 9 Meters Biopharma (NMTR) today indicate a series of insider buys at the company. In the post-market, 9 Meters shares have added ~18.0% in reaction ...